BI
BIOA.US BioAge Labs, Inc
- Market cap
- USD 255M
- P/E
- -
- P/B
- 0.75x
- ROE
- -31.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BIOA.US undervalued?
Graham numberThe Graham number of BioAge Labs, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioAge Labs, Inc fundamental analysis
No fundamental analysis for BioAge Labs, Inc yet.
BioAge Labs, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic car…
Full company profileBioAge Labs, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioAge Labs, Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.67M | 1.54M | 2.17M | 8.27M | 14.9M | 0.00 | 0.00 | 0.00 | 9.00M | 7.36M |
| Gross Profit | -23.8K | -4.50M | -441K | -5.39M | -7.38M | - | - | - | 9.00M | 7.28M |
| Operating Income | -41.2M | -35.2M | -38.5M | -29.6M | -110M | -40.0M | -48.4M | -78.2M | -92.8M | -123M |
| EBITDA | -38.8M | -45.0M | -33.1M | -13.3M | -88.7M | -39.4M | -55.9M | -68.6M | -79.7M | -109M |
| Net Income | -33.2M | -46.4M | -37.2M | -22.5M | -98.2M | -39.7M | -63.9M | -71.1M | -80.6M | -109M |
| EPS | -1.18 | -1.65 | -1.32 | -0.66 | -2.34 | -1.16 | -1.87 | -1.98 | -2.24 | -2.38 |
| Balance Sheet | ||||||||||
| Total Assets | 114M | 152M | 143M | 161M | 69.5M | 28.4M | 25.9M | 358M | 295M | 368M |
| Total Liabilities | 49.1M | 94.9M | 96.7M | 113M | 47.7M | 141M | 199M | 35.1M | 22.8M | 21.2M |
| Shareholders' Equity | 65.0M | 57.5M | 46.4M | 48.5M | 21.9M | -113M | -173M | 323M | 272M | 346M |
| Cash & Short-term Investments | 83.7M | 51.0M | 6.97M | 16.2M | 4.63M | 27.6M | 21.6M | 354M | 281M | 284M |
| Total Debt | 29.7M | 37.6M | 40.1M | 52.3M | 37.6M | 2.47M | 53.3M | 8.70M | 5.56M | 2.73M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -27.5M | -22.5M | -32.2M | -37.6M | -29.8M | -36.2M | -37.4M | -51.5M | -81.6M | -99.0M |
| Capital Expenditure | 12.8M | 0.00 | 0.00 | 0.00 | 0.00 | 103K | 166K | 366K | 719K | 496K |
| Free Cash Flow | -40.3M | -22.5M | -32.2M | -37.6M | -29.8M | -36.3M | -37.5M | -51.9M | -82.3M | -99.5M |
| Ratios | ||||||||||
| ROE | -51.1% | -80.7% | -80.3% | -46.4% | -449.2% | - | - | -22.0% | -29.6% | -31.5% |
| ROA | -29.1% | -30.5% | -26.0% | -13.9% | -141.2% | -139.7% | -246.3% | -19.8% | -27.3% | -29.7% |
| Net Profit Margin | -1,246.3% | -3,008.5% | -1,713.9% | -271.7% | -656.8% | - | - | - | -896.1% | -1,482.6% |
| Debt to Equity | 0.46x | 0.65x | 0.86x | 1.08x | 1.72x | - | - | 0.03x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioAge Labs, Inc dividends
BioAge Labs, Inc has not paid dividends in the last 9 fiscal years.
Who owns BioAge Labs, Inc
- Insiders 2.36%
- Institutions 94.69%
- Public & others 2.95%
- Shares outstanding 46.0M
- Free float 39.3M
Top funds holding BIOA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.14M | 2.48% | 0.00% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.02M | 2.21% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 814K | 1.77% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 456K | 0.99% | +2.88% | Oct 2026 |
| iShares Russell 2000 Value ETF | 266K | 0.58% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 247K | 0.54% | -0.19% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 245K | 0.53% | -1.48% | Sep 2026 |
| Fidelity Small Cap Index | 226K | 0.49% | -41.34% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 212K | 0.46% | +0.27% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 204K | 0.45% | +42.93% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 204K | 0.44% | +0.24% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 202K | 0.44% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 189K | 0.41% | +20.25% | Sep 2026 |
| JPMorgan US Small Company L | 186K | 0.40% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 186K | 0.40% | -8.26% | Sep 2026 |
| Bridge Builder Small Cap Fund | 175K | 0.38% | +128.99% | Oct 2026 |
| Franklin Biotechnology Discovery A | 133K | 0.29% | -1.48% | Sep 2026 |
| iShares US Pharmaceuticals ETF | 132K | 0.29% | +0.33% | Oct 2026 |
| Dimensional US Small Cap ETF | 117K | 0.26% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 98.2K | 0.21% | -23.12% | Sep 2026 |
Top institutions holding BIOA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.85M | 6.21% | +25.63% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.39M | 5.21% | -17.30% | Jun 2026 |
| Sofinnova Ventures | 2.29M | 5.00% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.14M | 4.67% | 0.00% | Jun 2026 |
| Octagon Capital Advisors LP | 1.75M | 3.81% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 1.67M | 3.64% | +1.27% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.67M | 3.63% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.54M | 3.36% | +13.97% | Jun 2026 |
| Polar Capital Holdings PLC | 1.07M | 2.34% | -5.32% | Jun 2026 |
| BRAIDWELL LP | 1.03M | 2.25% | -13.95% | Jun 2026 |
| State Street Corp | 1.02M | 2.23% | +20.05% | Jun 2026 |
| Geode Capital Management, LLC | 1.00M | 2.19% | +34.03% | Jun 2026 |
| Sands Capital Ventures, LLC | 786K | 1.71% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 752K | 1.64% | +5.67% | Jun 2026 |
| D. E. Shaw & Co LP | 743K | 1.62% | +6.23% | Jun 2026 |
| Balyasny Asset Management LLC | 703K | 1.53% | -47.06% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 653K | 1.42% | 0.00% | Jun 2026 |
| Cosmic Management, LLC | 502K | 1.09% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 500K | 1.09% | +26.84% | Sep 2026 |
| StemPoint Capital LP | 464K | 1.01% | -31.47% | Jun 2026 |
BioAge Labs, Inc company profile
- Company name
- BioAge Labs, Inc
- Ticker
- BIOA.US
- Exchange
- USA Stocks
- Listed since
- Sep 26, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 60
- Fiscal year end
- December
- Address
- 5885 Hollis Street, EmeryVille, CA, United States, 94608
- Phone
- 510 806 1445
- Website
- bioagelabs.com
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BioAge Labs, Inc management
10- Dr. Kristen Fortney Ph.D.Co-Founder, CEO, President, Treasurer, Secretary & Director · born 1984
- Dr. Eric Morgen M.D.Co-Founder, COO & Director · born 1983
- Dr. Paul D. Rubin M.D.Chief Medical Officer & Executive VP of Research · born 1954
- Dr. Dov A. Goldstein M.B.A., M.D.Chief Financial Officer · born 1967
- Mr. Shane Barton CPASenior Vice President of Finance & Accounting · born 1971
- Mr. Rusty Montgomery Ph.D.Senior Vice President of Research
- Ms. Julie GammelgardSenior Vice President of People
- Dr. Peng Leong M.B.A., Ph.D.Chief Business Officer & Therapeutic Area Head of Brain Aging
- Mr. BJ Sullivan Ph.D.Chief Strategy Officer
- Ms. Ann C. Neale RN BSNChief Development Officer